A LinkedIn post from Tubulis highlights the company’s planned participation in the LSX World Congress Europe in Lisbon from March 25–26. According to the post, Chief Business Officer Ingo Lehrke is scheduled to speak in the Opening Keynote Fireside Chat, focusing on Tubulis’ development since its 2019 founding.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that Lehrke will discuss key inflection points in Tubulis’ trajectory and the company’s efforts to advance the therapeutic potential of antibody-drug conjugates (ADCs) for patients worldwide. For investors, this visibility at a high-profile industry conference may support Tubulis’ positioning within the oncology and ADC ecosystem, potentially aiding future partnering, capital-raising, and business development opportunities.